Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

doi:10.1200/JCO.2011.35.2682

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2011

Arun Banu, Bayraktar Soley, Liu Diane D, Gutierrez Barrera Angelica M, Atchley Deann, Pusztai Lajos, Litton Jennifer Keating, Valero Vicente, Meric-Bernstam Funda, Hortobagyi Gabriel N, Albarracin Constance

Abstract excerpt

PURPOSE: To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST) in patients with breast cancer with and without deleterious BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: A total of 317 women who underwent BRCA genetic testing and were treated with NST for breast cancer between 1997 and 2009 were included in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to Disease-Free Survival

Share to Genes, BRCA1

Share to Logistic Models

Share to Neoadjuvant Therapy

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 21900106
DOI: 10.1200/JCO.2011.35.2682
PMCID: PMC4874218

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.PMID 21900106Read ↗

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.Semantic proximity Read ↗

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.Semantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.Semantic proximity Read ↗

Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.Semantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.